Mekinist

Trametinib, the active ingredient in Mekinist, is a MEK inhibitor presented as a tablet for oral use. It targets cancers that harbor BRAF V600E or V600K mutations, including melanoma, non‑small cell lung cancer, anaplastic thyroid cancer and colorectal cancer, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Mekinist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing and ensuring quality and regulatory compliance.

Mekinist (trametinib) is indicated for malignancies driven by the MAPK pathway, particularly those with BRAF V600 mutations.

- BRAF V600E/K mutation‑positive melanoma: improves progression‑free survival in adult patients. - Non‑small cell lung cancer with KRAS G12C mutation (in combination therapy): contributes to disease control. - Anaplastic thyroid cancer with BRAF V600E mutation: offers a targeted treatment option. - Colorectal cancer with BRAF V600E mutation (in combination): enhances therapeutic response.

Adverse reactions to trametinib may vary in frequency and severity.

Common Side Effects: - Diarrhea - Rash or acneiform dermatitis - Nausea - Fatigue - Peripheral edema - Stomatitis

Serious or Rare Side Effects: - Interstitial lung disease or pneumonitis - Decreased left ventricular ejection fraction or cardiomyopathy - Severe hepatic injury (elevated transaminases) - Ocular toxicity such as retinal vein occlusion - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hemorrhage or bleeding events

When prescribing trametinib, clinicians should consider several safety measures.

- Dose adjustments: required for patients with moderate to severe hepatic impairment. - Cardiac monitoring: obtain baseline and periodic left ventricular ejection fraction assessments. - Dermatologic evaluation: monitor for severe rash, skin ulceration, or other cutaneous reactions. - Ophthalmologic assessment: perform baseline eye exam and periodic monitoring for retinal disorders. - Pregnancy and lactation: avoid use due to unknown safety; discuss risks with a specialist. - Store below 25°C: keep in the original pack, protect from moisture.

Trametinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce trametinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase trametinib plasma levels. - Co‑administration with other MEK inhibitors: heightened risk of overlapping toxicities. - QT‑prolonging agents: increased potential for cardiac arrhythmias. - Anticoagulants combined with anti‑angiogenic agents: elevated bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise trametinib concentrations. - Acid‑reducing agents (e.g., proton‑pump inhibitors): could affect drug absorption. - Systemic corticosteroids: may mask early skin toxicity. - Live vaccines: should be avoided during treatment. - Herbal supplements such as St. John’s wort: may alter metabolic clearance.